Compare Extra Space Storage, Inc. (EXR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Extra Space Storage, Inc. trades at $134.5 (market cap $28.12B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Extra Space Storage, Inc. is far larger — about 250.6× Inovio Pharmaceuticals Inc's market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EXR | INO | |
|---|---|---|
Market Cap | $28.12B | $112.19M |
Volume | 2,595,579 | 3,201,278 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $2.65 |
52-Week Low | $126.67 | $0.66 |
Typical Hold Time | 109 Days | 43 Days |
Enterprise Value | $41.84B | $83.51M |
Dividend Yield | 4.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $134.65, up 2.24% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38B in 2025, and net income margin stands at 27.79%. Analyst consensus is split evenly between Buy and Hold, with a price target of $158.33. Recent news highlights leadership transition and dividend declarations.
Outlook is balanced: solid operational performance and dividend yield support the stock, but high valuation ratios and bearish technicals pose near-term risks. Investors should weigh strong fundamentals against potential volatility from interest rate sensitivity and market sentiment shifts.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
